Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPASIL-ESIDRIX #1 vs ALDORIL D50
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reserpine depletes catecholamines (norepinephrine, dopamine) from central and peripheral nerve endings by irreversibly inhibiting the vesicular monoamine transporter (VMAT2), leading to reduced sympathetic outflow and vasodilation. Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption.
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Hypertension
Hypertension (first-line or second-line therapy),Hypertensive urgency (off-label)
1 tablet orally twice daily, titrate to response. Each tablet contains reserpine 0.1 mg and hydrochlorothiazide 25 mg.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
Reserpine: 50-100 hours (terminal); clinical effects persist due to irreversible adrenergic neuron blockade. Hydrochlorothiazide: 6-15 hours (terminal).
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Reserpine: extensive hepatic metabolism; Hydrochlorothiazide: not significantly metabolized, excreted unchanged in urine.
Methyldopa is extensively metabolized in the liver via conjugation and O-methylation, with involvement of catechol-O-methyltransferase (COMT). Hydrochlorothiazide is not extensively metabolized; it is eliminated largely unchanged by the kidneys.
Reserpine: renal (30% as metabolites, <1% unchanged), fecal (60% as metabolites). Hydrochlorothiazide: renal (>95% unchanged).
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
Reserpine: 96% bound to albumin. Hydrochlorothiazide: 68% bound to plasma proteins.
~20% bound to albumin; minimal binding to other plasma proteins.
Reserpine: 6-8 L/kg (extensive tissue binding, especially adrenergic neurons). Hydrochlorothiazide: 0.8-1.0 L/kg (enters erythrocytes).
0.2–0.3 L/kg (moderately low Vd, indicating limited extravascular distribution and predominantly plasma water distribution).
Reserpine: oral 30-50% (presystemic metabolism). Hydrochlorothiazide: oral 65-75%.
Oral: 30–40% (due to extensive first-pass metabolism); IV: 100%.
e GFR 30-50 m L/min: reduce dose by 50% or extend interval. e GFR <30 m L/min: contraindicated due to thiazide ineffectiveness.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min: reduce dose and monitor electrolytes.
Child-Pugh A: standard dosing. Child-Pugh B: reduce reserpine dose by 50%. Child-Pugh C: avoid use.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: contraindicated.
Reserpine: 0.005-0.02 mg/kg/day orally in 1-2 divided doses. Hydrochlorothiazide: 1-2 mg/kg/day orally in 2 divided doses. Adjust per response.
Not recommended; inadequate safety data.
Start at half the standard dose (0.5 tablet orally daily). Titrate slowly due to increased sensitivity to hypotension, CNS depression, and electrolyte disturbances.
Start with 1 tablet (hydrochlorothiazide 12.5 mg + methyldopa 125 mg) once daily; increase slowly; monitor for hypotension and electrolyte imbalance.
None
None
May cause mental depression, including suicidal risk,Electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia),Orthostatic hypotension,Increased risk of arrhythmias with digoxin,May exacerbate systemic lupus erythematosus,May activate peptic ulcer,Monitor renal function and electrolytes
Sedation and drowsiness common; avoid driving or hazardous activities. Risk of Coombs-positive hemolytic anemia with methyldopa (discontinue if anemia develops). Hepatotoxicity and liver function abnormalities (discontinue if jaundice occurs). Orthostatic hypotension; caution in volume-depleted patients. Electrolyte imbalances (particularly hypokalemia, hyponatremia) with hydrochlorothiazide; monitor serum electrolytes. Sulfonamide cross-sensitivity possible. Exacerbation of systemic lupus erythematosus. Avoid abrupt withdrawal of methyldopa (may cause rebound hypertension).
History of mental depression or suicidal thoughts,Active peptic ulcer,Ulcerative colitis,Electroconvulsive therapy (ECT) within 2 weeks,Anuria,Hypersensitivity to reserpine, hydrochlorothiazide, or sulfonamides
Active hepatic disease (cirrhosis, hepatitis) associated with methyldopa therapy; previous methyldopa-induced liver disorders. Anuria or hypersensitivity to thiazide diuretics or sulfonamide-derived drugs. Concomitant use with MAO inhibitors. Severe renal impairment (creatinine clearance <30 m L/min) or electrolyte depletion due to hydrochlorothiazide. Concurrent lithium therapy (risk of lithium toxicity).
Avoid high-potassium foods (bananas, oranges, leafy greens) if taking potassium-sparing agents, but this combination does not include them. Limit sodium intake to enhance antihypertensive effect. Avoid grapefruit juice as it may increase reserpine absorption. Maintain adequate fluid intake but avoid excessive water intake due to risk of hyponatremia.
Avoid potassium supplements or salt substitutes containing potassium without consulting doctor. Limit alcohol intake. Avoid excessive grapefruit juice. Maintain adequate potassium intake through diet to prevent hypokalemia.
First trimester: Reserpine crosses placenta; associated with increased risk of congenital malformations (neural tube defects, cardiovascular anomalies) based on animal data and limited human reports. Second/third trimester: Use associated with fetal bradycardia, hypotonia, hypothermia, respiratory depression, and meconium ileus due to catecholamine depletion; risk of neonatal hypotension and poor feeding. Avoid in pregnancy unless benefit outweighs risk.
Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester may cause fetal/neonatal effects including electrolyte disturbances, jaundice, thrombocytopenia, and possible fetal growth restriction. Methyldopa has not shown teratogenicity. Aldoril D50 (M 500mg/HCTZ 50mg) is not recommended during pregnancy, especially after first trimester.
Reserpine excreted in breast milk; M/P ratio not established. Concentrations may be low but can cause infant respiratory depression, nasal congestion, and cyanosis. Hydrochlorothiazide also excreted; may suppress lactation. Contraindicated during breastfeeding.
Both methyldopa and HCTZ are excreted in breast milk. Methyldopa M/P ratio approximately 1.0; HCTZ M/P ratio variable, small amounts. Use during breastfeeding may suppress lactation due to HCTZ diuretic effect. Monitor infant for signs of hypotension, electrolyte imbalance. Caution recommended; use only if clearly needed.
No established safe dose; if unavoidable, use lowest effective dose. Pregnancy-induced hemodilution and increased renal clearance may reduce drug levels; however, due to toxicity, dose adjustment not recommended. Consider alternative antihypertensives (e.g., labetalol, nifedipine).
Pregnancy-induced increase in plasma volume may reduce effectiveness of HCTZ, requiring dose adjustment. Methyldopa pharmacokinetics not significantly altered; however, increased clearance in pregnancy may require higher doses. In preeclampsia, dose adjustments may be needed. Avoid HCTZ in pregnancy if possible.
Serpasil-Esidrix #1 combines reserpine (a Rauwolfia alkaloid) and hydrochlorothiazide (a thiazide diuretic). Reserpine depletes catecholamines and serotonin, causing gradual BP reduction. Onset of antihypertensive effect is delayed (2-3 weeks). Monitor for depression, nasal congestion, and extrapyramidal effects. Hydrochlorothiazide may cause hypokalemia, hyponatremia, and hyperglycemia. Avoid use in patients with history of depression, peptic ulcer, or electrolyte imbalances. Combination product offers convenience but fixed dosing limits titration.
ALDORIL D50 combines methyldopa and hydrochlorothiazide. Monitor for orthostatic hypotension, especially in volume-depleted patients. May cause positive Coombs test, hemolytic anemia, and lupus-like syndrome. Avoid in pheochromocytoma. Use caution in hepatic disease.
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Do not stop abruptly; sudden withdrawal may cause rapid blood pressure rise.,Report symptoms of depression, mood changes, or unusual tiredness promptly.,Avoid alcohol, which may increase dizziness and drowsiness.,Use sun protection; this drug increases photosensitivity risk.,Monitor for signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat.,Weigh yourself regularly and report rapid weight gain or swelling.,Avoid potassium supplements or salt substitutes unless directed by your doctor.
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Report unexplained fever, jaundice, or dark urine immediately.,Avoid sudden discontinuation; may cause rapid increase in blood pressure.,Stay hydrated but do not overhydrate; monitor for signs of electrolyte imbalance.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPASIL-ESIDRIX #1 vs ALDORIL D50, answered by our medical review team.
SERPASIL-ESIDRIX #1 is a Antihypertensive Combination that works by Reserpine depletes catecholamines (norepinephrine, dopamine) from central and peripheral nerve endings by irreversibly inhibiting the vesicular monoamine transporter (VMAT2), leading to reduced sympathetic outflow and vasodilation. Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption.. ALDORIL D50 is a Antihypertensive Combination that works by Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPASIL-ESIDRIX #1 and ALDORIL D50 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPASIL-ESIDRIX #1 is: 1 tablet orally twice daily, titrate to response. Each tablet contains reserpine 0.1 mg and hydrochlorothiazide 25 mg.. The standard adult dose of ALDORIL D50 is: 1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPASIL-ESIDRIX #1 and ALDORIL D50 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPASIL-ESIDRIX #1 is classified as Category C. First trimester: Reserpine crosses placenta; associated with increased risk of congenital malformations (neural tube defects, cardiovascular anomalies) based on animal data and lim. ALDORIL D50 is classified as Category C. Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.